Today, we will see why we should remain in wait-and-see mode for Radius Health (RDUS) until the end of 2020.
Company overview
Radius Health is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative endocrine therapeutics. Founded in 2003, the company went public in 2014.
The company's lead asset, Tymlos (abaloparatide) injection, is approved by the FDA for the treatment of PMO (postmenopausal women with osteoporosis) at high risk for fracture. Radius Health is also studying abaloparatide injection for potential use in the treatment of men with osteoporosis and abaloparatide